Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 10, 2002, Pages 439-450

  Park, J W ^a   Siekmeier, R ^a   Merz, M ^a   Krell, B ^a   Harder, S ^a   Marz W ^a   Seidel, D ^a   Schuler S ^a   Grosse W ^a  

^a BfArM   (Germany)

Author keywords

Cholesterol; Cyclosporin A; Heart transplantation; HMG CoA reductase inhibitor; Lipoproteins; Pravastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PREDNISONE; TRIACYLGLYCEROL; TRIAMCINOLONE ACETONIDE;

ADULT; AREA UNDER THE CURVE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL CHEMISTRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; PHARMACOLOGICAL PARAMETERS; RECIPIENT; REVIEW;

EID: 0036792736     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40439     Document Type: Review

References (32)

1. Appel S, Dingemanse J 1996 Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 32: 39-55
2. Arnadottir M, Eriksson LO, Thysell H, Karkas JD 1993 Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney-transplant recipients with and without cyclosporine. Nephron 65: 410-413
3. Ballantyne CM, Podet FJ, Patsch WP, Harati Y, Appel V, Gotto AM, Young JB 1989 Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53-56
4. Ballantyne CM, Bourge RC, Domalik LJ, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Radovancevic B, Taylor DO, Ventura HO, Yancy, CW, Young JB 1996 Treatment of hyperlipidemia after heart transplantation and rationale for the heart-transplant lipid registry. Am J Cardiol 78: 532-535
5. Blumenthal RS 2000 Statins: effective antiatherosclerotic therapy. Am Heart J 139: 577-583
6. Bottorff M, Hanstenn P 2000 Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med 160: 2273-2280
7. Campana C, Regazzi MB, Buggia I, Molinaro M 1996 Clinically significant drug interactions with cyclosporine. An update. Clin Phannacokinet 30: 141-179
8. Castelao AM, Grinyo JAL Castineiras MJ, Fiol C, Gilvernet S, Seron D, Torras J, Cruzado JM, Alsina J 1995 Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc 27: 2217-2220
9. Desager JP, Horsmans Y 1996 Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 31: 348-371
10. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use ofthe preparative ultracentrifuge. Clin Chem 18: 499-502
11. Goldberg R, Roth D 1996 Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal-transplant recipients taking cyclosporine. Transplantation 62: 1559-1564
12. Haria M, McTavish D 1997 Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 53: 299-336
13. Heinzel G, Woloszczak R, Thomann P 1993 TopFit: Version 2.0; pharmacokinetic and pharmacodynamic data analysis system for the PC. Fischer, Stuttgart
14. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Terasaki PI, Danovitch GM 1996 The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 61: 1469-1474
15. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW 1995 Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-627
16. LaRosa JC, He J, Vupputuri S 1999 Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 282: 2340-2346
17. Lennernäs H, Fager G 1997 Pharmacodynamics and pharmacokinefics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32: 403-425
18. Lye WC, Hughes K, Leong SO, Tan CC, Lee EJC 1995 Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant Proc 27: 977-978
19. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U 1997 Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62: 311-321
20. Omar MA, Wilson JP, Cox TS 2001 Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35: 1096-1107
21. Park JW, Merz M, Braun P Vermeltfoort M 1996 Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 15: 572-579
22. Quion JAV, Jones PH 1994 Clinical pharmacokinetics of pravastatin. Clin Pharmakokinet 27: 94-103
23. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A, Vigano M 1993 Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25: 2732-2734
24. Rudas L, Pflugfelder PW McKenzie FN, Menkis AH, Novick RJ, Kostuk WJ 1990 Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 66: 1135-1138
25. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins M, Keech A, Packard C, Simes J, Byington R, Furberg CD for the Prospective Pravastatin Pooling Project In vestigators Group 2000 Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 102: 1893-1900
26. Schrama YC, Hene RJ, de Jonge N, Joles JA, van Rijn HJM, Bär DR, Ververs TFT, van Tol A, Koomans HA 1998 Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac- and renal-transplant recipients. An exercise provocation test. Transplantation 66: 1175-1181
27. Siekmeier R, Groβ W, März W 2000 Determination of pravastatin by high-performance liquid chromatography. Int J Clin Pharm Ther 38: 419-425
28. Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, MacMahon S, Shaw J, Simes RJ, Thompson PL, White HD, Hunt D for the LIPID Study Group 2000 Effects of pravastatin in 3260 patients with unstable angina: results from the Lipid Study. Lancet 356: 1871-1875
29. Yoshimura N, Oka T, Okamoto M, Ohmori Y 1992 The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 53: 94-99
30. Yoshimura N, Ohmori Y, Tyuji T, Oka T 1994 Effect of pravastatin on renal transplant recipients treated with cyclosporine 4-year follow-up. Transplant Proc 26: 2632-2633
31. Watanabe T, Kokubu N, Charnick SB, Naito M, Tsuruo T, Cohen D 1997 Interaction of cyclosporine derivatives with the ATPase activity of human P-glycoprotein. Br J Pharmacol 122: 241-248
32. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B 1997 Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation 96: 1398-1402